2001
Isoniazid Preventive Therapy, Hepatitis C Virus Infection, and Hepatotoxicity among Injection Drug Users Infected with Mycobacterium tuberculosis
Sadaphal P, Astemborski J, Graham N, Sheely L, Bonds M, Madison A, Vlahov D, Thomas D, Sterling T. Isoniazid Preventive Therapy, Hepatitis C Virus Infection, and Hepatotoxicity among Injection Drug Users Infected with Mycobacterium tuberculosis. Clinical Infectious Diseases 2001, 33: 1687-1691. PMID: 11641824, PMCID: PMC2650436, DOI: 10.1086/323896.Peer-Reviewed Original ResearchConceptsHepatitis C virusInjection drug usersTuberculosis infectionValue elevationDrug usersCurrent injection drug useLatent Mycobacterium tuberculosis infectionHepatitis C virus infectionHepatitis B surface antigenLow HCV prevalenceC virus infectionIsoniazid preventive therapyInjection drug useM. tuberculosis infectionMycobacterium tuberculosis infectionHIV-1 infectionHuman immunodeficiency virusB surface antigenConcurrent alcohol useDrug discontinuationHCV prevalencePreventive therapyImmunodeficiency virusProspective studyTransaminase values
1998
Molecular and Geographic Patterns of Tuberculosis Transmission After 15 Years of Directly Observed Therapy
Bishai W, Graham N, Harrington S, Pope D, Hooper N, Astemborski J, Sheely L, Vlahov D, Glass G, Chaisson R. Molecular and Geographic Patterns of Tuberculosis Transmission After 15 Years of Directly Observed Therapy. JAMA 1998, 280: 1679-1684. PMID: 9831999, DOI: 10.1001/jama.280.19.1679.Peer-Reviewed Original ResearchConceptsEpidemiologic linkObserved therapyTuberculosis casesTuberculosis transmissionRecent transmissionTraditional contact investigationsCulture-positive tuberculosisTuberculosis control measuresCases of tuberculosisCommon risk factorsProportion of casesHigher drug useLow socioeconomic statusProportion of diseaseContact investigationEpidemiologic evidenceM tuberculosisRisk factorsEpidemiologic comparisonsEpidemiologic linkageTuberculosis accountsInformation system dataTraditional contact tracingDrug useEarly identificationMycobacterium tuberculosis infection and disease are not associated with protection against subsequent disseminated M. avium complex disease
Sterling T, Moore R, Graham N, Astemborski J, Vlahov D, Chaisson R. Mycobacterium tuberculosis infection and disease are not associated with protection against subsequent disseminated M. avium complex disease. AIDS 1998, 12: 1451-1457. PMID: 9727565, DOI: 10.1097/00002030-199812000-00006.Peer-Reviewed Original ResearchMeSH KeywordsAdolescentAdultAIDS-Related Opportunistic InfectionsAntibiotic ProphylaxisAntitubercular AgentsCD4 Lymphocyte CountCohort StudiesFemaleHumansMaleMiddle AgedMycobacterium avium ComplexMycobacterium avium-intracellulare InfectionMycobacterium tuberculosisProspective StudiesRisk FactorsSubstance Abuse, IntravenousTuberculosisConceptsM. tuberculosis infectionM. avium complex diseaseMycobacterium tuberculosis infectionDisseminated MACTuberculosis infectionExtrapulmonary tuberculosisDrug useLow CD4 cell levelsProspective observational cohort studyAdult HIV clinicIntravenous Experience cohortPrior opportunistic infectionsCD4 cell levelsObservational cohort studyLogistic regression analysisALIVE cohortAntibiotic prophylaxisMAC prophylaxisAntiretroviral therapyCD4 lymphocytesHIV clinicMAC diseaseActive tuberculosisCohort studyOpportunistic infections
1996
Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation.
Goletti D, Weissman D, Jackson R, Graham N, Vlahov D, Klein R, Munsiff S, Ortona L, Cauda R, Fauci A. Effect of Mycobacterium tuberculosis on HIV replication. Role of immune activation. The Journal Of Immunology 1996, 157: 1271-8. PMID: 8757635, DOI: 10.4049/jimmunol.157.3.1271.Peer-Reviewed Original ResearchMeSH KeywordsAcquired Immunodeficiency SyndromeCD4 Lymphocyte CountCD8-Positive T-LymphocytesCell DeathHIV-1HumansLymphocytesMycobacterium tuberculosisTuberculinTuberculosisVirus ReplicationConceptsHIV replicationMTB diseaseMycobacterium tuberculosisLymph node mononuclear cellsViral replicationCellular activationProtein derivative positivityPlasma viral loadAg-specific activationT cell-depleted lymphocytesPPD-negative donorsHIV diseaseHIV infectionAcute phaseViral loadImmune activationMononuclear cellsPPD positivityHealthy donorsHIV epidemicT cellsPrimary PBMCsHIV infection modelEpidemiology dataHIV